MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Aileron Therapeutics EPS Ratio 2011-2026 | ALRN
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Aileron Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.51 | -3.42 | -6.02 | -5.89 | -0.61 | -1.2 | -2.14 | -3.04 | -42.4 | -32.3 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.61 | -42.4 | -10 |
Quarterly EPS Ratio Aileron Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.21 | -0.28 | -0.25 | - | -0.27 | -0.45 | -0.86 | - | -0.4 | -0.39 | -1.05 | - | -1.4 | -1.76 | -1.86 | - | -0.07 | -0.06 | -0.08 | -0.12 | -0.13 | -0.14 | -0.24 | -0.26 | -0.28 | -0.26 | -0.49 | -0.48 | -0.5 | -0.64 | -0.52 | -0.47 | -0.45 | -11 | -10.6 | -10.3 | -9.84 | -12.9 | -9.25 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.06 | -12.9 | -2.24 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M |  USA |
 |
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | USA |
 |
AbCellera Biologics
ABCL
|
-0.49 | $ 3.55 | -0.28 % | $ 1.06 B |  Canada |
 |
Adagene
ADAG
|
-0.59 | $ 3.91 | -2.01 % | $ 220 M |  China |
 |
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M | Canada |
 |
AC Immune SA
ACIU
|
-0.97 | $ 3.32 | 6.07 % | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M | China |
 |
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | USA |
 |
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M |  France |
 |
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-13.7 | - | -10.17 % | $ 12.2 K | USA |
 |
ADC Therapeutics SA
ADCT
|
-3.77 | $ 4.11 | -2.61 % | $ 105 M | Schweiz |
 |
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
Aptorum Group Limited
APM
|
-0.78 | $ 0.79 | 0.04 % | $ 4.31 M | China |
 |
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M | USA |
 |
argenx SE
ARGX
|
-7.99 | $ 706.03 | 0.39 % | $ 25 B |  Niderland |
 |
Alterity Therapeutics Limited
ATHE
|
-0.53 | $ 3.34 | -7.48 % | $ 8.04 B |  Australia |
 |
Ascendis Pharma A/S
ASND
|
-8.28 | $ 228.06 | -1.28 % | $ 5 B |  Danmark |
 |
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-1.77 | - | -0.23 % | $ 916 M | USA |
 |
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-0.01 | $ 3.43 | -4.19 % | $ 7.46 B |  Israel |
 |
Allena Pharmaceuticals
ALNA
|
-0.72 | - | 3.16 % | $ 1.9 M | USA |
 |
AlloVir
ALVR
|
-2.85 | - | 4.14 % | $ 49.1 M | USA |
 |
Anika Therapeutics
ANIK
|
-5.64 | $ 14.51 | 1.04 % | $ 213 M | USA |
 |
Aptinyx
APTX
|
-0.96 | - | -39.0 % | $ 4.57 M | USA |
 |
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | USA |
 |
Aptose Biosciences
APTO
|
-36.4 | - | -45.71 % | $ 1.2 M | Canada |
 |
Arcturus Therapeutics Holdings
ARCT
|
-2.4 | $ 6.39 | -3.62 % | $ 175 M | Israel |
 |
BioNTech SE
BNTX
|
42.2 | $ 94.86 | 4.77 % | $ 27.2 B | Germany |
 |
CureVac N.V.
CVAC
|
-2.21 | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | USA |
 |
Burford Capital Limited
BUR
|
75.3 | $ 8.28 | 2.86 % | $ 1.34 B | Britain |
 |
Athira Pharma
ATHA
|
-2.52 | - | - | $ 269 M | USA |
 |
Athersys
ATHX
|
-0.39 | - | 3.77 % | $ 22.4 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
-1.27 | $ 1.14 | 2.7 % | $ 34.3 M | USA |
 |
Avenue Therapeutics
ATXI
|
-15.8 | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-0.86 | $ 1.51 | - | $ 385 M | Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-1.63 | - | - | $ 521 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-1.94 | $ 6.13 | 1.32 % | $ 500 M | USA |
 |
AVROBIO
AVRO
|
0.27 | - | 1083.1 % | $ 745 M | USA |
 |
Equillium
EQ
|
-0.38 | $ 2.15 | -7.33 % | $ 74.7 M | USA |